Cefmenoxime (CMX)の前立腺組織内移行に関する検討

Abstract

26症例を対象とし, CMX 2 gを1時間かけて点滴静注したところ, 血清内濃度は点滴終了時に最高濃度124 μg/mlに達し, 前立腺内濃度は, それより9.4分遅れて最高濃度35.7 μg/gに達して以後血清同様半減期1.07時間で速やかに減少した.CMXはその抗菌力と前立腺組織内移行度からみて前立腺炎および前立腺摘除後の感染に対して有効であると考えられた.その際の組織内移行に度は, 前立腺の組織型による差はなかったが, 前立腺重量が大きいほど低下する傾向がみられた

The concentrations of Cefmenoxime (CMX) were examined in the serum and prostatic tissue of 25 patients with benign prostatic hypertrophy and of 1 patient with prostatic carcinoma. The CMX levels were measured at scheduled intervals after 2 g CMX administration by one hour drip infusion prior to prostatectomy. Pharmacokinetic analysis was performed based on the two compartment open model theory. 1) Maximum serum level of CMX was 124 micrograms/ml at the end of drip infusion and the biological half-life was 1.07 hrs. 2) CMX concentration in prostatic tissue reached a maximum level of 35.7 cg/g at 1.16 hrs after the start of CMX administration. Ratio of prostatic tissue to serum level in the area under curve (AUC) was 33% and biological half-life was 1.07 hrs. These results suggested that the CMX concentration in the prostatic tissue was higher than the MIC80 against pathogenic bacteria, particularly E.coli and Klebsiella sp. for a relatively long time. For this reason CMX is one of the more preferred drugs for treatment of chronic prostatitis and post-operative infection of prostate.